CPhI Japan, leading chemical and pharma event, which enables the industry to network and source, bringing together leaders and decision-makers in pharmaceutical ingredients sector will be held from April 20 to 22, 2016 at Big Sight Exhibition Centre, Tokyo, Japan.
The expo will have the co- located events - ICSE for contract manufacturing and services; P-MEC| LAB World for pharmaceutical and laboratory machinery, technology and equipment; BioPh for biopharmaceutical development and services and InnoPack for pharmaceutical packaging and drug delivery systems with access to the ultimate one-stop-shop for all Japanese pharma solutions.
The event is being organised by UBM EMEA, which operates as a leading global exhibition brand and their complementary media products.
The show would bring together over 16,000 pharma professionals for three days of networking, business development and excellence having a host of events that will cover all aspects of the pharmaceutical supply chain.
The event would be focussing on innovations, interactive and educational programmes to network, learn and gain new insights into the world of pharma.
The CPhI Japan conference will provide a wide range of free seminars and paid conferences on trending industry topics providing a valuable insight into the Japanese pharma industry. Over 9,000 pharma professionals have been attending these sessions every year. The conference would provide information about the industry, various products, services, new launches, innovations and news during a 30-minute presentation for visitors and exhibitors.
The event will also have a customised matchmaking system which will facilitate quality meetings through an online system that would allow the visitors to search and select exhibitors, hand-picked to their specifications, actively seek partnerships, products and services.
The event is a perfect platform to successfully enter the highly profitable Japanese market and attending the seminars and conferences will provide a competitive advantage that will help with success in the world's second-largest pharma market.